Does Rallies show 13F holders for AKTS?

Yes. Rallies tracks hedge fund and 13F ownership data for AKTS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AKTS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AKTS. It does not provide personalized investment advice.

AKTS (Aktis Oncology, Inc. Common stock) Stock Analysis - Hedge Fund Holdings

Aktis Oncology, Inc. Common stock (AKTS) is a publicly traded the market company. As of May 21, 2026, AKTS trades at $19.04 with a market cap of $1.03B and a P/E ratio of -9.99. AKTS moved +3.03% today. Year to date, AKTS is +24873.80%; over the trailing twelve months it is flat. Its 52-week range spans $0.03 to $29.16. Analyst consensus is strong buy with an average price target of $33.50. Rallies surfaces AKTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AKTS stock?

Hedge funds tracked by Rallies that own AKTS include Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aktis Oncology, Inc. Common stock.

AKTS Key Metrics

Key financial metrics for AKTS
Metric	Value
Price	$19.04
Market Cap	$1.03B
P/E Ratio	-9.99
EPS	$-1.89
Dividend Yield	0.00%
52-Week High	$29.16
52-Week Low	$0.03
Volume	200
Avg Volume	0
Revenue (TTM)	$27.38M
Net Income	$-167.95M
Gross Margin	-2.52%

Top Hedge Funds Holding AKTS

Soros Fund holds 100.00K shares of AKTS, changed +0.00% as of Mar 31, 2026.

Latest AKTS News

Aktis Oncology Raises $365.4M IPO, Launches Phase 1b AKY-2519 Trial in mCRPC — May 11, 2026
Aktis Oncology Secures $318M in Upsized IPO Priced at $18 Per Share — Jan 9, 2026

Recent AKTS Insider Trades

Foley Todd bought 232.87K (~$4.19M) on Jan 12, 2026.
MPM BIOVENTURES 2018, L.P. bought 1.11M (~$20.03M) on Jan 12, 2026.
GADICKE ANSBERT bought 1.11M (~$20.03M) on Jan 12, 2026.

AKTS Analyst Consensus

4 analysts cover AKTS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.50.

Common questions about AKTS

Who owns AKTS stock?: Hedge funds tracked by Rallies that own AKTS include Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aktis Oncology, Inc. Common stock.
Does Rallies show 13F holders for AKTS?: Yes. Rallies tracks hedge fund and 13F ownership data for AKTS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AKTS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AKTS. It does not provide personalized investment advice.